RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studiedIn the event that you also missed this because you were once again caught up in your conspiracy "bot" stuf .... " the evolving metastatic pancreatic cancer arm of the Goblet Phase 2 study involving pelareorep + atezolizumsb + n-paclitaxel had the following still maturing findings at the time of the trial cut-off date : an overall response rate (ORR) of 62% (54% confirmed by two or more scans), a Disease Control Rate (DCR) of 85%, 7.2 months of median progression-free survival (mPFS), interim median overall survival (imOS) of 10.6 months, and expansion of both pre-existing and new T-cell clones."
https://www.prnewswire.com/